News
10 Nov 2020
Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec’s T-SPOT® Technology – is Published by Public Health England and Oxford Immunotec
READ MORE
5 Nov 2020
Oxford Immunotec Files Submission to Food and Drug Administration (FDA) for the T-Cell Select™ Reagent Kit
READ MORE
22 Oct 2020
UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials
READ MORE
29 Sep 2020
Oxford Immunotec Announces Food and Drug Administration (FDA) Clearance of the T-SPOT®.TB Test for Use in Pediatrics Over the Age of Two
READ MORE
20 Sep 2020
Oxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT® DiscoveryTM SARS-CoV-2 Test
READ MORE
20 Jul 2020
Oxford Immunotec Announces Agreement with Stop TB Partnership – Global Drug Facility (GDF) to Provide Access to the T-SPOT®.TB Test for 100+ TB Burden Countries
READ MORE
Page : 1 | 2 | 3 | 4 | 5 | 6 | Prev | Next